Clinical Trials Browser

Phase 2 × Terminated × Lenalidomide × Clear all

NCT05090566 2026-04-24

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

Phase 2 Terminated

46 enrolled 15 charts

Multiple Myeloma

NCT01316523 2025-11-21

Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma

Phase 2 Terminated

30 enrolled 10 charts

Lymphoma, Non-Hodgkin

NCT03376477 2025-08-27

Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission

Phase 2 Terminated

24 enrolled 8 charts

Multiple Myeloma

NCT05288062 2025-08-20

Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma

Phase 2 Terminated

17 enrolled 9 charts

Smoldering Multiple Myeloma, Multiple Myeloma

NCT05788289 2025-05-25

A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma

Phase 2 Terminated

4 enrolled 8 charts

Lymphoma, Mantle-Cell

NCT00848328 2025-04-24

Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma

Phase 2 Terminated

LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04352205 2024-07-01

Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure

Phase 2 Terminated

Multiple Myeloma, Renal Insufficiency

NCT05328102 2024-04-30

Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)

Phase 2 Terminated

3 enrolled 6 charts

Lymphoma, Large B-Cell, Diffuse, Pyloric Stenosis, Hypertrophic

NCT02294357 2023-11-01

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

Phase 2 Terminated

Multiple Myeloma, Recurrence

NCT03733691 2023-10-25

Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients

Phase 2 Terminated

Multiple Myeloma

NCT02906332 2023-08-22

Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)

Phase 2 Terminated

12 enrolled 10 charts

Multiple Myeloma

NCT01307605 2023-06-27

Rituximab With or Without Lenalidomide in Treating Patients With Previously Untreated Follicular Lymphoma

Phase 2 Terminated

Lymphoma, Lymphoma, Follicular

NCT03411031 2023-03-29

Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide

Phase 2 Terminated

18 enrolled 11 charts

Multiple Myeloma

NCT02225275 2022-09-28

Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 2 Terminated

9 enrolled 9 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01241786 2022-07-20

VZCLLPI0146

Phase 2 Terminated

5 enrolled 10 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02128230 2021-06-22

UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

Phase 2 Terminated

20 enrolled 7 charts

Multiple Myeloma

NCT02309515 2021-01-19

Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis

Phase 2 Terminated

12 enrolled 8 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02897830 2020-11-12

IFM2014-03

Phase 2 Terminated

Multiple Myeloma

NCT00899431 2020-01-27

Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)

Phase 2 Terminated

39 enrolled 10 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00655668 2019-11-25

EXPECT

Phase 2 Terminated

54 enrolled 13 charts

Lymphoma, Non-Hodgkin, Lymphoma, T-Cell

NCT03333746 2019-05-30

Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 2 Terminated

1 enrolled 5 charts

Multiple Myeloma

NCT01374217 2018-12-10

Administration of Tadalafil in Conjunction With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma

Phase 2 Terminated

14 enrolled 8 charts

Multiple Myeloma

NCT01924169 2018-09-20

Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)

Phase 2 Terminated

3 enrolled 7 charts

LymphoidOther hematologic neoplasm

Agammaglobulinemia, Hematologic Diseases, Influenza, Human, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02720510 2018-07-24

PANORAMA4

Phase 2 Terminated

6 enrolled 7 charts

Multiple Myeloma

NCT01779167 2018-07-11

THRiL for WM

Phase 2 Terminated

4 enrolled 5 charts

Waldenstrom Macroglobulinemia

NCT00538824 2018-06-06

DexTR

Phase 2 Terminated

5 enrolled 8 charts

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT01675141 2018-02-05

Lenalidomide Maintenance Therapy for Multiple Myeloma

Phase 2 Terminated

11 enrolled 7 charts

Multiple Myeloma

NCT01442714 2018-01-03

Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS

Phase 2 Terminated

33 enrolled 11 charts

MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT01518465 2017-11-29

Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma

Phase 2 Terminated

Multiple Myeloma

NCT01419795 2017-07-27

Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant

Phase 2 Terminated

3 enrolled 10 charts

DermatologicLymphoidOther hematologic neoplasm

Burkitt Lymphoma, Immunoblastic Lymphadenopathy, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Intraocular Lymphoma

NCT00843310 2017-07-19

Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma

Phase 2 Terminated

8 enrolled 6 charts

Multiple Myeloma

NCT01729338 2017-05-31

Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma

Phase 2 Terminated

17 enrolled 16 charts

Multiple Myeloma

NCT00482911 2017-03-27

Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma

Phase 2 Terminated

12 enrolled 10 charts

Uveal Melanoma

NCT01600053 2016-12-15

Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia

Phase 2 Terminated

11 enrolled 4 charts

LymphoidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01401322 2016-11-28

Single Agent Lenalidomide in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

Phase 2 Terminated

5 enrolled 5 charts

LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01121757 2016-09-12

Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma

Phase 2 Terminated

11 enrolled 12 charts

Lymphoma, Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT00751296 2016-06-16

Rev-CLL

Phase 2 Terminated

27 enrolled 7 charts

LymphoidOther hematologic neoplasm

Leukemia, B-Cell

NCT00142168 2016-04-21

CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia

Phase 2 Terminated

16 enrolled 10 charts

Waldenstrom Macroglobulinemia

NCT00567229 2015-11-20

Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma

Phase 2 Terminated

3 enrolled 6 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02353468 2015-03-09

Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant

Phase 2 Terminated

3 enrolled 5 charts

Multiple Myeloma

NCT00720850 2013-09-27

LENAMAINT

Phase 2 Terminated

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT01617213 2013-06-21

AMM-2011

Phase 2 Terminated

Multiple Myeloma

NCT01032291 2013-05-21

A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer

Phase 2 Terminated

51 enrolled 12 charts

Gastrointestinal

Colorectal Neoplasms

NCT00684242 2013-01-28

Lenalidomide (Revlimid) for the Treatment of Refractory Cancer Pain

Phase 2 Terminated

4 enrolled 5 charts

Cancer Pain, Pain

NCT00968331 2012-08-27

Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Phase 2 Terminated

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT01036399 2012-08-27

Study of Lenalidomide (Revlimid) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Patients

Phase 2 Terminated

Lymphoma, T-Cell, Peripheral

NCT01222195 2012-08-07

Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)

Phase 2 Terminated

1 enrolled 5 charts

MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes

NCT01127542 2011-12-05

RESPeCT

Phase 2 Terminated

LymphoidOther hematologic neoplasm

Leukemia, B-Cell

NCT00474188 2009-09-02

A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase 2 Terminated

26 enrolled 5 charts

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT00179738 2005-11-23

A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer.

Phase 2 Terminated

Prostatic Neoplasms